Lexicon Pharmaceuticals (LXRX) EBITDA Margin (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) reported EBITDA Margin of 5.7% for Q1 2026, up 200611.0% year-over-year from N/an in Q1 2025, and up 97.98% quarter-over-quarter from 282.71% in Q4 2025.
Lexicon Pharmaceuticals (LXRX) EBITDA Margin (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has 16 years of EBITDA Margin data on file, last reported at 5.7% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 5.7%, up 200611.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 37.69% (up 53011.0% YoY), and the FY2025 annual result was 101.26%, up 54323.0% from the prior year.
- EBITDA Margin climbed to 5.7% in Q1 2026 per LXRX's latest filing, from 282.71% in the prior quarter.
- Over five years, EBITDA Margin peaked at 11.13% in Q2 2025 and troughed at 31196.3% in Q3 2023.
- A 4-year average of 5473.82% and a median of 2632.25% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin surged 2752378 bps in 2024, then tumbled 15468 bps in 2025.
- A 4-year view of EBITDA Margin shows it stood at 6476.76% in 2023, then jumped by 98 bps to 128.03% in 2024, then sank by 121 bps to 282.71% in 2025, then jumped by 98 bps to 5.7% in 2026.
- Business Quant data shows LXRX's EBITDA Margin at 5.7% in Q1 2026, 282.71% in Q4 2025, and 89.73% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Lexicon Pharmaceuticals | 804.48 Mn | 633.82 Mn | 20.99 Mn | -5.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.70% |
| Dec 31, 2025 | -282.71% |
| Sep 30, 2025 | -89.73% |
| Jun 30, 2025 | 11.13% |
| Mar 31, 2025 | -2,011.81% |
| Dec 31, 2024 | -128.03% |
| Sep 30, 2024 | -3,672.51% |
| Jun 30, 2024 | -3,252.70% |
| Mar 31, 2024 | -4,435.32% |
| Dec 31, 2023 | -6,476.76% |
| Sep 30, 2023 | -31,196.30% |
| Jun 30, 2023 | -14,145.43% |
| Dec 31, 2021 | 9,019.72% |
| Jun 30, 2021 | -7,725.21% |
| Mar 31, 2021 | -77,581.48% |
| Dec 31, 2020 | 23.30% |
| Jun 30, 2020 | -278,476.00% |
| Mar 31, 2020 | -823.04% |
| Dec 31, 2019 | -585.42% |
| Sep 30, 2019 | 76.77% |